ProSpecBio has announced the launch of its new CHO cell–derived recombinant Activin-A, now available for immediate delivery worldwide.
Activin-A is increasingly recognised as a potential therapeutic agent for conditions such as brain injury and inflammatory diseases.
Studies have shown that it can help reduce damage and inflammation, making it a vital tool for researchers exploring new treatments and breakthroughs in these critical areas.
“By introducing recombinant Activin-A into our portfolio, we aim to accelerate discoveries in neuroscience, immunology and regenerative medicine,” said Nadav Amarant, Managing Director at ProSpecBio.
“Our mission is to deliver cutting-edge, reliable proteins that empower researchers and scientists worldwide to push the boundaries of science.”
With its CHO cell-derived purity and reliability, ProSpecBio’s Activin-A recombinant protein provides laboratories and academic institutions with the quality and consistency required for groundbreaking research.
This product expands ProSpecBio’s cytokine-related product line, reinforcing its position as a trusted partner to researchers globally.